Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, SynBiotic SE's Enterprise Value is €17.43 Mil.
SynBiotic SE's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-26.00 Mil. Therefore, SynBiotic SE's EV-to-EBIT ratio for today is -0.67.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, SynBiotic SE's Enterprise Value is €17.43 Mil.
SynBiotic SE's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €-7.49 Mil. Therefore, SynBiotic SE's EV-to-EBITDA ratio for today is -2.33.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, SynBiotic SE's Enterprise Value is €17.43 Mil.
SynBiotic SE's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €8.17 Mil. Therefore, SynBiotic SE's EV-to-Revenue ratio for today is 2.13.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, SynBiotic SE's Enterprise Value is €17.43 Mil.
SynBiotic SE's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €0.00 Mil. Therefore, SynBiotic SE's EV-to-FCF ratio for today is .
SynBiotic SE Enterprise Value Historical Data
The historical data trend for SynBiotic SE's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of SynBiotic SE's Enterprise Value
For the Drug Manufacturers - Specialty & Generic subindustry, SynBiotic SE's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SynBiotic SE's Enterprise Value Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, SynBiotic SE's Enterprise Value distribution charts can be found below:
* The bar in red indicates where SynBiotic SE's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
SynBiotic SE's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SynBiotic SE (FRA:SBX) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
SynBiotic SE's current Enterprise Value is €17.43 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. SynBiotic SE's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-26.00 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
SynBiotic SE's current Enterprise Value is €17.43 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. SynBiotic SE's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €-7.49 Mil.
SynBiotic SE's current Enterprise Value is €17.43 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. SynBiotic SE's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €8.17 Mil.
SynBiotic SE's current Enterprise Value is €17.43 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. SynBiotic SE's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SynBiotic SE Enterprise Value Related Terms
Thank you for viewing the detailed overview of SynBiotic SE's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
SynBiotic SE is engaged in the development of Phyto-cannabinoids and other herbal compounds concentrated molecules as well as the development of wellness products. The company engages in synthetic production, drug development, cannabinoids, dietary supplements and cosmetic products. Geographical presence in Germany, Austria, UK, Switzerland and Other countries. Majority of its revenue comes from domestic market.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:SBX has been successfully added to your 